A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
Public ClinicalTrials.gov record NCT06019728. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Study to Investigate Safety and Tolerability of Higher Infusion Rate to shORten the duraTion of FabrazymE Infusion
Study identification
- NCT ID
- NCT06019728
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 8 participants
Conditions and interventions
Conditions
Interventions
- AGALSIDASE BETA (GZ419828) Drug
- Acetaminophen Drug
- Diphenhydramine Drug
- Dexamethasone Drug
- Montelukast Drug
- Loratadine Drug
- Cetirizine Drug
- Fexofenadine Drug
Drug
Eligibility (public fields only)
- Age range
- 2 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 9, 2023
- Primary completion
- Oct 24, 2024
- Completion
- Oct 24, 2024
- Last update posted
- Oct 20, 2025
2023 – 2024
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Medical Center Site Number : 1003 | Santa Monica | California | 90404 | — |
| Emory University School of Medicine Site Number : 1005 | Atlanta | Georgia | 30322-1007 | — |
| Infusion Associates Site Number : 1001 | Grand Rapids | Michigan | 49525 | — |
| Metropolitan Hospital Center Site Number : 1004 | New York | New York | 10021 | — |
| Lysosomal and Rare Disorders Research and Treatment Center, Inc Site Number : 1002 | Fairfax | Virginia | 22030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06019728, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2025 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06019728 live on ClinicalTrials.gov.